Skip to content


Nanodotax is NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for several oncological conditions such as breast cancer, head and neck cancer and prostate cancer. . The toxicity profile of docetaxel is unfavorable and limiting its use, however. By formulating docetaxel for local intratumoral administration, the observed systemic toxicity can be avoided. In addition, with direct administration into the tumor higher docetaxel concentrations can be accomplished. LIDDS has performed proof-of-principle (PoP) studies of nanodotax in a relevant animal lung cancer model. The data showed good efficacy of local administration of nanodotax and without the systemic toxicity that was observed with systemically administered docetaxel. Clinical development of nanodotax was initiated in 2019 in patients with superficial solid tumors. The phase I study was terminated in late 2021 showing good safety and tolerability with few, mild and local side effects. Furthermore, an upregulation of important systemic immune-regulating biomarkers was observed that are believed to be important in turning cold tumors hot and in providing better conditions for treatment with check-point inhibitors. The next step in this program is to evaluate the mechanism of action in a smaller clinical study in prostate cancer patients that are scheduled for surgical removal of their tumor. This will be a unique possibility for investigating the local and systemic effects of nanodotax.